Obesity is classified by the World Health Organization as a chronic, relapsing disease, and mainstream treatment guidance now reflects that framing. But the rules for defining and treating it are still contested. Body mass index, the standard diagnostic tool, is widely acknowledged to be a rough measure, and experts disagree about how much weight loss matters and which treatments deserve first-line status.
This explainer walks through how the guidance evolved, what current sources recommend, and where the disagreement sits. It is information, not medical advice. Anyone with symptoms or a specific weight-related concern should bring it to a clinician.
According to the World Health Organization's fact sheet, more than 1 billion people worldwide were living with obesity in 2022, and adult obesity has more than doubled since 1990. That scale is one reason guidance keeps changing: a condition this common forces medicine to decide what it is and what to do about it.
How is obesity defined, and why does the definition matter?
Obesity is excess body fat at a level that can harm health. For adults, the WHO defines it as a body mass index of 30 or higher, and overweight as a BMI of 25 or higher. BMI is calculated as weight in kilograms divided by height in meters squared. Children are measured differently, using growth references that account for age and sex.
The definition matters because it drives everything downstream: who gets a diagnosis, which treatments guidelines cover, and how insurers and health systems respond. According to Cleveland Clinic's patient overview, clinicians also use obesity classes — class 1 is a BMI of 30 to under 35, class 2 is 35 to under 40, and class 3 is 40 or above — and may measure waist circumference, where the CDC identifies more than 35 inches in women or 40 inches in men as a risk factor for cardiovascular disease or type 2 diabetes.
The weakness in this system is well documented. Cleveland Clinic states plainly that BMI does not accurately predict specific health risks, and the WHO calls it a surrogate marker of fatness that additional measurements can refine. That tension sits at the center of the current debate about guidelines.
Why is obesity now called a chronic disease?
The biggest shift in mainstream guidance is framing. The WHO describes obesity as a chronic, relapsing disease arising from complex interactions between genetics, neurobiology, eating behaviors, access to healthy food, market forces, and the broader environment. That is a deliberate move away from the older idea of obesity as a simple failure of willpower.
The evidence behind that framing comes from what the condition does in the body. Cleveland Clinic explains that enlarged fat cells secrete hormones and other chemicals that cause inflammation, which can lead to insulin resistance, high blood pressure, and metabolic syndrome. The condition raises the risk of cardiovascular disease, type 2 diabetes, fatty liver disease, gallstones, kidney disease, sleep apnea, arthritis, and certain cancers. In 2021, the WHO attributes an estimated 3.7 million deaths from noncommunicable diseases to higher-than-optimal BMI. For related coverage, see Kindergarten Vaccine Exemptions Reached a Record High for 2025-2026, CDC Data Show.
Not every authority has signed on. Reference summaries of the condition note that while the WHO, the American Medical Association, and several national governments classify obesity as a disease, some others, including the United Kingdom, do not. The disagreement is not cosmetic: disease status affects funding, coverage, and how clinicians are trained to treat it.
What do current treatment guidelines actually recommend?
Treatment guidance follows a stepped pattern. Diet and exercise remain the foundation recommended by health professionals, according to reference overviews of the condition. Medications can be added to reduce appetite or decrease fat absorption. If those steps are not effective, procedures such as a gastric balloon or metabolic surgery may be used to reduce stomach volume or change nutrient absorption. Metabolic surgery is described as working through more than restriction — it induces sustained changes in gut hormones involved in appetite and metabolic regulation.
One figure appears consistently across sources: modest weight loss carries real benefit. Cleveland Clinic states that studies show losing even 5 to 10 percent of current weight can reduce the risk of premature death from all causes. That point matters for readers who assume treatment only counts if it produces dramatic results.
Practical steps a reader can discuss with a clinician include:
- Getting a full assessment, not just a BMI number — waist measurement, metabolic labs, and medication review all inform the picture.
- Asking which current medications may contribute to weight gain; Cleveland Clinic lists antidepressants, steroids, anti-seizure medications, some diabetes medications, and beta-blockers among examples.
- Discussing sleep and stress, since the same overview links short sleep and stress hormones to disrupted hunger regulation.
- Asking a doctor the specific question: "Given my BMI class and health history, which treatment steps make sense first, and what evidence supports them?"
Diet quality is part of the picture, and readers can find more detail in the site's guide to what to know about dietary fiber. Physical activity guidance sits in the site's workouts section.
Where do experts still disagree?
Three disagreements run through the current debate.
First, the diagnostic tool. BMI is easy to measure and consistent across countries, which is why guidelines keep using it. But it cannot distinguish fat from muscle, and it says nothing about where fat is carried — a factor the waist-circumference thresholds exist to address. Proposals to supplement or replace BMI appear regularly in medical commentary, and no replacement has achieved consensus.
Second, the disease label. The WHO's classification as a chronic, relapsing disease has been adopted by major medical bodies, but holdouts remain, as noted above. Critics worry the label medicalizes a condition shaped heavily by environment; supporters argue it matches the biology and reduces stigma. Both positions appear in the reference literature.
Third, expectations. Reference summaries note that while many people with obesity attempt to lose weight and are often successful, maintaining weight loss long-term is rare. That finding pushes some experts toward long-term or indefinite treatment models, the way other chronic diseases are managed, while others caution about lifelong medication. The WHO also stresses that obesity is a societal responsibility, pointing to food environments and regulation rather than individual choices alone — a framing that shifts the policy debate as much as the clinical one.
What remains uncertain is how these threads resolve. Newer drug treatments have changed the conversation, but the sources reviewed here do not settle questions about long-term safety, who should start medication, or how BMI should be supplemented. Readers should treat any headline claiming the debate is over with caution.
When to see a clinician
This section is the practical heart of the piece. A clinician visit is warranted when weight changes without a clear cause, when screening shows elevated blood sugar or blood pressure, or when symptoms of sleep apnea, joint pain, or breathlessness appear. Cleveland Clinic notes that obesity itself causes no specific symptoms, which makes periodic assessment more important, not less.
Urgent evaluation is appropriate for chest pain, severe breathlessness, or symptoms of uncontrolled blood sugar. For routine concerns, the exact question to ask is: "What is my BMI class, what does my waist measurement add, and which of my current conditions or medications should shape a weight plan?"
Prevention guidance from public health agencies emphasizes environment as much as individual behavior, a theme explored in the site's prevention coverage. Readers wanting the broader context of how health guidance shifts can follow the cover story series.
The takeaway
The evidence establishes several things clearly. Obesity affects more than 1 billion people worldwide. It is now formally classified as a chronic, relapsing disease by the WHO and major medical bodies, though not universally. Treatment guidance runs from diet and exercise through medication to surgery, and even 5 to 10 percent weight loss reduces mortality risk. What remains unsettled is the measurement — BMI's limits are acknowledged by the very bodies that use it — and the long-term model of care. The honest summary is that guidance has moved toward treating obesity as a chronic disease, while the tools for defining it and the expectations for treating it are still being argued out.
